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Introduction
============

Calreticulin is a Ca^2+^-binding chaperone found in the lumen of the endoplasmic reticulum (ER)[\*](#fn1){ref-type="fn"} ([@bib27]). The protein binds monoglucosylated oligosaccharides ([@bib3]; [@bib17]) and misfolded proteins ([@bib34]), and it is believed to play a critical role in quality control processes during protein synthesis and folding ([@bib17]). Several studies indicate that increased expression of calreticulin increases the Ca^2+^ storage capacity of the ER ([@bib27]). It also appears to modulate store-operated Ca^2+^ influx ([@bib2]; [@bib25]; [@bib12]; [@bib36]) and to alter Ca^2+^ transport by the sarcoplasmic/endoplasmic reticulum Ca^2+^-ATPase, SERCA2b ([@bib19]). Evidence now indicates that Ca^2+^-binding chaperones in the lumen of the ER affect luminal Ca^2+^ concentrations (\[Ca^2+^\]~ER~) ([@bib24]) and that agonist-induced changes in \[Ca^2+^\]~ER~ affect ER function ([@bib7]).

Mice homozygous for calreticulin gene disruption (*crt* ^−^ *^/^*−) showed a marked decrease in ventricular wall thickness and in deep intertrabecular recesses in the ventricular walls, indicating that calreticulin is essential for proper cardiac development ([@bib26]; [@bib33]). Agonist-induced Ca^2+^ release via the inositol 1,4,5-trisphosphate (InsP~3~) pathway is inhibited in *crt* ^−^ *^/^*− cells as is Ca^2+^-dependent translocation of nuclear factor in activated T cells ([@bib26]). These results indicate that calreticulin, in addition to being a chaperone, plays a critical role in Ca^2+^ homeostasis.

In these studies, we used calreticulin-deficient mouse embryonic fibroblasts to examine the in vivo function of calreticulin as a regulator of Ca^2+^ homeostasis. In cells without calreticulin, the ER has a lower capacity for storage of Ca^2+^, although the free \[Ca^2+^\]~ER~ as measured by an ER-targeted "cameleon" reporter is not changed. Bradykinin-induced Ca^2+^ release is inhibited in calreticulin-deficient cells, yet they release Ca^2+^ in response to InsP~3~. Apparently, *crt* ^−^ *^/^*− cells fail to produce measurable levels of InsP~3~ in response to bradykinin, likely because of impaired binding of bradykinin to its cell surface receptor. Our findings suggest that in calreticulin-deficient cells altered folding of the bradykinin receptor adversely affects its ability to initiate InsP~3~-dependent Ca^2+^ release and that different domains of calreticulin may play distinct functions in the lumen of ER.

Results
=======

Calreticulin-deficient mouse embryonic fibroblasts
--------------------------------------------------

To determine the effects of calreticulin deficiency on ER function, we isolated mouse embryonic fibroblasts from *crt* ^−^ *^/^*− and wild-type embryos. These cell lines were designated K41 for wild-type mouse embryonic fibroblasts and K42 for calreticulin-deficient mouse embryonic fibroblasts. Some of the calreticulin-deficient cells (K42) were also transfected with a calreticulin expression vector and were designated K42CRT. As expected, Western blot analysis revealed that the K41 and K42CRT cells contained immunoreactive calreticulin ([Fig. 1](#fig1){ref-type="fig"} A, lanes 1 and 3), whereas the K42 *crt* ^−^ *^/^*− cells did not ([Fig. 1](#fig1){ref-type="fig"} A, lane 2). The morphological appearance of the wild-type (K41) and calreticulin-deficient (K42) cells was indistinguishable and typical of fibroblasts ([Fig. 1](#fig1){ref-type="fig"} B). The cell lines all attached firmly to plastic, and we detected no differences in the kinetics of their long-term (14 d) growth (unpublished data). [Fig. 1](#fig1){ref-type="fig"} C shows that K41 and K42CRT cells both expressed calreticulin and that the protein was localized to an ER-like network. As expected, there was no expression of calreticulin in K42 cells. Morphologically, at a light microscope level the ER appeared intact in all cell lines as judged by staining with antibodies against protein disulfide isomerase (PDI) and Grp94 ([Fig. 1](#fig1){ref-type="fig"} C). We observed typical nuclear morphology in all of the cell lines and the actin cytoskeleton visualized by labeling with fluorescent phalloidin also appeared normal (unpublished data).

![**Calreticulin-deficient mouse embryonic fibroblasts.** (A) Western blot analysis of calreticulin in mouse embryonic fibroblasts. Wild-type (K41) and calreticulin-deficient (K42) cells were lysed, and proteins were separated by SDS-PAGE, transferred to nitrocellulose membrane, and probed with anticalreticulin antibodies. Lane 1, wild-type K41 mouse embryonic fibroblasts; lane 2, calreticulin-deficient (*crt^−^* ^/*−*^) K42 mouse embryonic fibroblasts; lane 3, calreticulin-deficient fibroblasts transfected with expression vector containing cDNA encoding calreticulin (K42CRT). (B) Phase--contrast analysis of K41 and K42 cells. (C) Immunostaining of K41, K42, and K42CRT cells with anti-CRT, anti-Grp94, and anti-PDI antibodies.](0102073f1){#fig1}

\[Ca^2**+**^\]~ER~ capacity in calreticulin-deficient cells
-----------------------------------------------------------

The overexpression of calreticulin leads to an increased total Ca^2+^ content in the lumen of the ER ([@bib27]). This indicates that calreticulin somehow alters the Ca^2+^ storage capacity of the ER. Therefore, we used ^45^Ca^2+^ to estimate the Ca^2+^ content of the ER in calreticulin-deficient cells ([@bib25]). Wild-type cells (K41) contained 44 ± 3 pmol of Ca^2+^/10^6^ cells, whereas the calreticulin-deficient cells (K42) contained 24 ± 4 pmol of Ca^2+^/10^6^ cells. Thus, the absence of calreticulin resulted in a \>1.8-fold reduction in cellular Ca^2+^ content.

Next, we used thapsigargin, an inhibitor of the Ca^2+^-ATPase, to measure the amount of Ca^2+^ associated with rapidly exchangeable stores. To measure the residual amounts of Ca^2+^ contained within thapsigargin-insensitive stores, we added the Ca^2+^ ionophore ionomycin. In these experiments, cells were equilibrium loaded with ^45^Ca^2+^ and then resuspended in a nonradioactive Ca^2+^-free medium ([@bib25]). [Fig. 2](#fig2){ref-type="fig"} shows that in response to thapsigargin the wild-type cells (K41) released almost twice as much ^45^Ca^2+^ as the calreticulin-deficient cells (K42). When the remaining ^45^Ca^2+^ was released with ionomycin, the amount released from K41 cells was greater than from K42 cells ([Fig. 2](#fig2){ref-type="fig"} A). [Fig. 2](#fig2){ref-type="fig"} A also shows that there was an increase in Ca^2+^ release in the presence of ionomycin compared with thapsigargin alone. This is likely due to ionomycin-dependent Ca^2+^ release from intracellular compartments other than ER including mitochondria. To confirm that the absence of calreticulin caused the decreased Ca^2+^ content of the K42 cells, some K42 cells were stably transfected with a calreticulin expression vector, creating the K42CRT cell line ([Fig. 1](#fig1){ref-type="fig"}). [Fig. 2](#fig2){ref-type="fig"} A shows that the Ca^2+^ content of thapsigargin-sensitive stores was indistinguishable in K42CRT and wild-type (K41) cells. We conclude that the absence of calreticulin in K42 cells causes a significant decrease in the Ca^2+^ content of thapsigargin-sensitive stores.

![**ER Ca^2^** ^+^ **content in calreticulin-deficient cells.** Calreticulin-deficient cells (K42) were transfected with expression vectors encoding calreticulin or calreticulin domains followed by measurement of a total cellular Ca^2+^. (A) A total cellular Ca^2+^ content was determined using equilibrium incubation with ^45^Ca^2+^ followed by addition of thapsigargin (estimates Ca^2+^ pool in thapsigargin-sensitive Ca^2+^ stores) or ionomycin (estimates Ca^2+^ pool in thapsigargin-insensitive Ca^2+^ stores) ([@bib25]). Ca^2+^ content was measured in wild-type (K41), *crt^−^* ^/*−*^ (K42), and K42 cells transfected with expression vectors encoding either calreticulin (K42CRT), the N + P domain of calreticulin (K42N+P), or the P + C domain of the protein (K42P+C). Data shown are means ± SE (*n* = 3). (B) Western blot analysis with anti-HA tag antibodies of K42 calreticulin-deficient cells expressing calreticulin domains. Lane 1, calreticulin-deficient cells (K42); lane 2, K42 cells transfected with expression vectors encoding the N + P domain of calreticulin (K42N+P); lane 3, K42 transfected with expression vector encoding the P + C domain of the protein (K42P+C). Similar levels of both, the 38-kD N + P domain and the 36-kD P + C domain were expressed in transfected cells.](0102073f2){#fig2}

The C domain of calreticulin affects ER Ca^2^+ storage capacity in vivo
-----------------------------------------------------------------------

K42 (*crt* ^−^ *^/^*−) cells provide us with an excellent tool for investigating the role of calreticulin\'s different domains in determining ER Ca^2+^ storage capacity in vivo. Calreticulin binds Ca^2+^ with high capacity to its COOH-terminal domain ([@bib27]), but the effects of this binding have not been documented in vivo. To investigate the effect of calreticulin\'s C domain on the Ca^2+^ storage capacity of thapsigargin-sensitive stores, we transfected K42 (calreticulin-deficient) cells with expression vectors encoding different domains of the protein. cDNA encoding N + P and P + C domain of calreticulin contained HA epitope for immunological detection of the recombinant proteins. Using anti-HA tag antibodies, we showed that calreticulin-deficient cells transfected with expression vectors encoding N + P or P + C domain expressed similar levels of both recombinant proteins ([Fig. 2](#fig2){ref-type="fig"} B). Despite numerous attempts, we have been unable to create a K42 (calreticulin-deficient) cell line expressing the C domain of calreticulin alone. Attempts to create other cell lines that overexpress the C domain of calreticulin (HeLa, HEK293, CHO) have also failed. This is probably because the C domain, when expressed alone, is very unstable ([@bib9]). However, we can express the C domain of calreticulin when the central P domain is also included ([Fig. 2](#fig2){ref-type="fig"} B, lane 3). Although the P domain of calreticulin also binds Ca^2+^, it binds only 1 mol/mol of protein with high affinity ([@bib27]). [Fig. 2](#fig2){ref-type="fig"} A shows that expression of the P + C domain in calreticulin-deficient K42 cells (*K42P*+C) dramatically increased thapsigargin-sensitive Ca^2+^ release compared with that seen in the parental K42 cell line. This indicates that the P + C domain of calreticulin modulates ER Ca^2+^ storage capacity. The reason for unusually high ER Ca^2+^ in the P + C domain--expressing cells is not clear at present. This may be due to an increased Ca^2+^ capacity of the P + C domain in the ER lumen in the absence of the N domain of calreticulin.

Next, we created K42 (calreticulin-deficient) cell lines expressing the N + P domain of calreticulin ([Fig. 2](#fig2){ref-type="fig"} A, *K42N*+P). We found no significant difference in Ca^2+^ storage capacity in K42 and K42N+P cells ([Fig. 2](#fig2){ref-type="fig"} A), indicating that neither the N domain nor the P domain of calreticulin modulates thapsigargin-sensitive (ER) Ca^2+^ storage capacity. Our results show that calreticulin via its C domain plays a role in determining the Ca^2+^ storage capacity of the ER.

Free \[Ca^2^+\]~ER~ in calreticulin-deficient cells
---------------------------------------------------

To determine the free \[Ca^2+^\]~ER~ in calreticulin-deficient cells, we transfected wild-type (K41) and calreticulin-deficient (K42) mouse embryonic fibroblasts with the ER-targeted cameleon YC4~ER~ ([@bib1]), a Ca^2+^ indicator, which relies on fluorescent proteins and calmodulin ([@bib28]). [Fig. 3](#fig3){ref-type="fig"} A shows that the cameleon was expressed in both cell types and was localized in a reticular pattern consistent with labeling of the ER. [Fig. 3](#fig3){ref-type="fig"} B shows that the free \[Ca^2+^\]~ER~ did not differ significantly in the wild-type cells (290 ± 18 μM Ca^2+^; mean ± SE; *n* = 18) and calreticulin-deficient cells (288 ± 20 μM Ca^2+^; mean ± SE; *n* = 22). In further studies, we used thapsigargin and ionomycin to completely deplete cellular Ca^2+^stores. Under these conditions, free \[Ca^2+^\]~ER~ was reduced to 27 ± 3 μM Ca^2+^ (mean ± SE; *n* = 15) in the wild-type cells and to 23 ± 3 μM Ca^2+^ (mean ± SE) in the calreticulin-deficient cells ([Fig. 3](#fig3){ref-type="fig"} B). Our results indicate that although the total Ca^2+^ content of the ER is significantly decreased in calreticulin-deficient cells, the free \[Ca^2+^\]~ER~ is unaltered both when Ca^2+^ stores are full and when they are depleted.

![**Free ER Ca^2^** ^+^ **luminal concentration in K41 wild-type and K42 calreticulin-deficient cells.** Cells were transiently transfected with YC4~ER~ and the ratio fluorescence calibrated to \[Ca^2+^\]~ER~ using calibration curves obtained in situ ([@bib1]). (A) Intracellular distribution of ER-targeted cameleon in wild-type (K41) and calreticulin-deficient (K42) cells. (A) Single wavelength cameleon fluorescence (emission at 535 nm) imaging of transfected cells revealing reticular pattern reminiscent of the ER. (B) Free \[Ca^2+^\]~ER~ in K41 wild-type (white bars) and K42 calreticulin-deficient (gray bars) cells was measured with ER-targeted cameleon as described under Materials and methods. TG, thapsigargin; iono, ionomycin. Data are derived from 15--22 independent experiments.](0102073f3){#fig3}

Bradykinin-induced Ca^2**+**^ release in calreticulin-deficient cells
---------------------------------------------------------------------

We next performed experiments with the Ca^2+^-sensitive fluorescent dye fura-2. [Fig. 4](#fig4){ref-type="fig"} shows that in wild-type (K41) cells, the resting free cytoplasmic Ca^2^+ concentration (\[Ca^2+^\]~c~) was ∼100 ± 12 nM (mean ± SD; *n* = 3). In calreticulin-deficient fibroblasts (K42), the resting free \[Ca^2+^\]~c~ was significantly increased (148 ± 10 nM; mean ± SD; *n* = 3). We also performed fura-2 analysis of \[Ca^2+^\]~c~ in calreticulin-deficient mouse embryonic fibroblasts, which had been transfected with a calreticulin expression vector (K42CRT cells). These cells, which express recombinant calreticulin, had 108 ± 13 nM (mean ± SD; *n* = 3) basal \[Ca^2+^\]~c~, indicating that reintroduction of calreticulin to calreticulin-deficient cells lowered the basal \[Ca^2+^\]~c~ to the levels observed in the wild-type (K41) cells ([Fig. 4, A and B](#fig4){ref-type="fig"}).

![**Bradykinin-induced Ca^2^** ^+^ **release in calreticulin-deficient cells.** Cells were loaded with the fluorescent Ca^2+^ indicator fura-2 and stimulated with 200 nM bradykinin. K41, wild-type mouse embryonic fibroblasts; K42, calreticulin-deficient cells; K42CRT, K42 cells transfected with calreticulin expression vector. (A) Represents typical traces showing bradykinin (BK) stimulation of cells in a Ca^2+^-free medium. Arrows indicate the time of addition of bradykinin. (B) Basal \[Ca^2+^\]~c~ in wild-type (white bar), calreticulin- deficient (black bar), and calreticulin-deficient cells transfected with calreticulin expression vector (hatched bar). The absolute values of \[Ca^2+^\]~c~ were: 100 ± 12 nM (K41), 148 ± 10 nM (*crt^−^* ^/*−*^ K42), and 95 ± 8 nM (*crt^−^* ^/*−*^ + CRT, K42CRT). (C) Ca^2+^ released by bradykinin was significantly different in cell lines investigated. K41, wild-type mouse embryonic fibroblasts; K42, calreticulin-deficient cells; K42CRT, K42 cells transfected with calreticulin expression vector. Data are mean ± SE (*n* = 3).](0102073f4){#fig4}

Next, we compared agonist-induced Ca^2+^ release in wild-type (K41) and calreticulin-deficient fibroblasts (K42). In preliminary experiments, we tested the effect of 100 μM carbachol, 1 μM angiotensin II, 50 nM bombesin, 200 nM bradykinin, and 25 ng PDGF/ml on Ca^2+^ release from the wild-type cells. Among all these agonists, only bradykinin resulted in Ca^2+^ release from the K41 cells, and so it was used in our subsequent experiments. Furthermore, in full agreement with our earlier report ([@bib26]) bradykinin caused a rapid and transient increase in the cytoplasmic Ca^2+^ concentration in wild-type (K41) cells but not in *crt* ^−^ *^/^*− (K42) cells, indicating that Ca^2+^ release via InsP~3~-dependent pathways is impaired in calreticulin-deficient cells ([Fig. 4, A and C](#fig4){ref-type="fig"}). To show that calreticulin is involved in this impairment, we investigated bradykinin-induced Ca^2+^ release in K42CRT cells. [Fig. 4, A and C](#fig4){ref-type="fig"}, show that the expression of calreticulin in K42 cells restored bradykinin-stimulated Ca^2+^ release. Importantly, the basal \[Ca^2+^\]~c~ was also decreased to levels observed in wild-type cells ([Fig. 4, A and B](#fig4){ref-type="fig"}).

In further experiments, we used a cameleon reporter to make time-resolved measurements of free \[Ca^2+^\]~ER~ in wild-type and calreticulin-deficient cells. Bradykinin by itself had little effects on \[Ca^2+^\]~ER~ (unpublished data) but caused a rapid \[Ca^2+^\]~ER~ decrease when thapsigargin was included to prevent ER refilling ([Fig. 5](#fig5){ref-type="fig"} A). A pronounced Ca^2+^ release was observed in wild-type cells, the \[Ca^2+^\]~ER~ decreasing to 80 ± 12 μM within 150 s. ([Fig. 5](#fig5){ref-type="fig"} C). Subsequent addition of ionomycin had little effects on the kinetics of the \[Ca^2+^\]~ER~ response ([Fig. 5](#fig5){ref-type="fig"} A), indicating the ER Ca^2+^ permeability was maximally activated by the combination of bradykinin and thapsigargin. In contrast, the addition of bradykinin and thapsigargin to calreticulin-deficient cells decreased \[Ca^2+^\]~ER~ only to 114 ± 18 μM ([Fig. 5](#fig5){ref-type="fig"} C), and subsequent addition of ionomycin caused a further decrease in \[Ca^2+^\]~ER~ ([Fig. 5](#fig5){ref-type="fig"} A). No differences were observed when thapsigargin was added alone, the \[Ca^2+^\]~ER~ decreasing with similar kinetics and to similar levels in wild-type and calreticulin-deficient cells ([Fig. 5, B and C](#fig5){ref-type="fig"}). The higher \[Ca^2+^\]~ER~ measured in calreticulin-deficient cells stimulated with bradykinin and thapsigargin thus likely reflects the failure of bradykinin to increase the ER Ca^2+^ permeability. These observations are in keeping with the fura-2 measurements presented in [Fig. 4](#fig4){ref-type="fig"} and indicate that bradykinin-induced Ca^2+^ release from the ER is impaired in the calreticulin-deficient K42 cells.

![**Free \[Ca^2^** ^+^ **\]~ER~ responses in bradykinin- and thapsigargin-stimulated cells.** Wild-type (K41) and calreticulin-deficient (K42) cells were transiently transfected with YC4~ER~ expression vector. A and B show the time-course of spatially averaged \[Ca^2+^\]~ER~ responses in cells stimulated with bradykinin and thapsigargin (BK + TG) or with thapsigargin alone. The responses were measured in Ca^2+^-free medium. When indicated, ionomycin (1 μM) was added to maximally deplete ER Ca^2+^ stores. (C) \[Ca^2+^\]~ER~ levels measured shortly after stimulation with bradykinin/thapsigargin or after full depletion of stores with thapsigargin. The absolute values were: 80 ± 12 μM (K41) and 114 ± 18 μM (K42) for BK + TG, and 44 ± 5 μM (K41) 53 ± 7 μM (K42) for depletion with TG. BK, bradykinin; TG, thapsigargin; iono, ionomycin. Data are mean ± SE. *n*, number of experiments.](0102073f5){#fig5}

SERCA2, the InsP~3~ receptor (InsP~3~R) and the bradykinin receptor in calreticulin-deficient cells
---------------------------------------------------------------------------------------------------

There are several potential explanations for the observation that bradykinin-induced Ca^2+^ release is impaired in calreticulin-deficient cells. For example, in *crt* ^−^ *^/^*− (K42) cells there could be changes in the expression and/or function of Ca^2+^ transport proteins in the ER or in the bradykinin receptor in the plasma membrane. To investigate these possibilities, we first compared expression of SERCA2 and the InsP~3~R in wild-type and calreticulin-deficient cells. [Fig. 6](#fig6){ref-type="fig"} A shows that the expression of SERCA2 was not altered in calreticulin-deficient cells. Further, the level of mRNA for SERCA was the same in wild-type (K41) and calreticulin-deficient (K42) cells (unpublished data). We also used Western blot analysis ([Fig. 6](#fig6){ref-type="fig"} B) and reverse transcriptase PCR ([Table I](#tbl1){ref-type="table"}) to compare expression of the three isoforms of the InsP~3~R (type 1, 2, and 3) in K41 and K42 cells. All three isoforms of the InsP~3~R were expressed in wild-type and *crt* ^−^ *^/^*− cells ([Fig. 6](#fig6){ref-type="fig"} B and [Table I](#tbl1){ref-type="table"}). However, we found a 30--40% reduction in mRNA for the InsP~3~R in calreticulin-deficient cells compared with the wild-type cells ([Table I](#tbl1){ref-type="table"}). Western blot analysis of types 1, 2, and 3 of the InsP~3~R revealed that these cells contain all three types of InsP~3~R at a ratio of 10:70:20 ([Fig. 6](#fig6){ref-type="fig"}). A significant decrease of ∼20% was found in the calreticulin-deficient K42 cells for InsP~3~R type 1 (3.1 ± 0.4 versus 2.6 ± 0.4; *n* = 4; *P* \< 0.01) and for InsP~3~R type 3 (9.4 ± 0.4 versus 7.5 ± 0.6; *n* = 4; *P* \< 0.01). The relative level of InsP~3~R type 2 was approximately equal in both cell types (0.2 ± 0.1; *n* = 4).

![**SERCA2 and InsP~3~R expression in calreticulin-deficient cells.** (A) Wild-type (K41) and calreticulin-deficient (K42) mouse embryonic fibroblasts were lysed, and an increasing amount of protein (from 4 to 30 μg) was separated in SDS-PAGE, transferred to nitrocellulose membrane, and probed with anti-SERCA2. (B) Microsomal vesicles were isolated from wild-type and calreticulin-deficient cells followed by protein separation in SDS-PAGE. InsP~3~R type 1 (InsP3R1), InsP~3~R type 2 (InsP3R2), and InsP~3~R type 3 (InsP3R3) proteins were identified by Western blot analysis. Lane 1, K41 cells; lane 2, K42 cells; lane 3, RBL-2H3 control cells. The lower molecular mass protein band in the InsP3R2 panel is an immunoreactive protein not related to InsP~3~R2, and it was not included in quantitative analysis. 50 μg protein/lane was loaded except for the InsP~3~R2 samples (100 μg protein/lane). The position of InsP~3~R is indicated by the arrow.](0102073f6){#fig6}

###### Quantitative analysis of mRNA encoding different isoforms of InsP~3~Rs in calreticulin-deficient K42 cells

     K41 wild-type cells   K42 calreticulin-deficient cells
  -- --------------------- ----------------------------------
     \%                    

Reverse transcriptase PCR was carried out as described in Materials and methods. GAPDH was used as an internal standard. Data are mean ± SD (*n* = 3).

Next, we compared expression of the bradykinin receptor and its targeting to the plasma membrane in wild-type (K41) and calreticulin-deficient (K42) cells. [Fig. 7](#fig7){ref-type="fig"} A shows that calreticulin-deficient cells had decreased level of bradykinin receptor protein. Quantitative analysis of Western blots indicated that there was ∼50% less bradykinin receptor in calreticulin-deficient cells compared with K41 wild-type cells. These results indicate that calreticulin deficiency had some effect on expression and/or turnover of the bradykinin receptor. Using confocal microscopy and antibodies against the bradykinin receptor, we found that the receptor was distributed in a "dotty" pattern across the cell surface in K41, K42, and K42CRT cells ([Fig. 7](#fig7){ref-type="fig"} B). We noticed no difference between the cell lines in distribution of the receptor ([Fig. 7](#fig7){ref-type="fig"} B). Cell surface localization of the receptor was further confirmed by flow cytometry assay using antibradykinin receptor antibodies. We observed no significant difference in the antibradykinin antibodies surface labeling of K41 and K42 cells ([Fig. 7](#fig7){ref-type="fig"} C), indicating the similar number of immunoreactive receptor protein molecules was present on cell surface. We concluded that in calreticulin-deficient cells the bradykinin receptor was properly targeted to and localized in the plasma membrane.

![**Expression of bradykinin receptor in calreticulin-deficient cells.** Mouse embryonic fibroblasts were harvested, lysed, and proteins were separated in SDS-PAGE, transferred to nitrocellulose membrane, and probed with antibradykinin receptor antibodies (A). The positions of molecular markers are indicated. The open arrowhead indicates the position of bradykinin receptor. (B) Localization of bradykinin receptor in wild-type (K41), calreticulin-deficient cells (K42), and calreticulin-deficient cells transfected with calreticulin expression vector (K42CRT). K42 mock-transfected control cells are also shown. In all cell lines, bradykinin receptor localizes to cell surface. (C) Bradykinin receptor expression on cell surface. Flow cytometry analysis of mouse embryonic fibroblasts was carried out with antibradykinin receptor antibodies. Results are presented as the relative mean fluorescence intensity after subtracting fluorescent values for the secondary antibodies alone. Results shown are representative of five experiments. K41, wild type cells; K42, calreticulin-deficient cells; BK, bradykinin receptor.](0102073f7){#fig7}

InsP~3~-induced Ca^2**+**^ release and InsP~3~ synthesis in calreticulin-deficient cells
----------------------------------------------------------------------------------------

We have shown that expression of the InsP~3~R is reduced in calreticulin-deficient (K42) cells, whereas expression of the bradykinin receptor is not. Therefore, we wanted to determine whether the altered expression of the InsP~3~R was responsible for the impairment of bradykinin-induced Ca^2+^ release in these cells. To test this hypothesis, we loaded wild-type and calreticulin-deficient cells with fluo-3, and then we added saponin to permeabilize the plasma membrane ([@bib13]). Subsequently, exogenous InsP~3~ was added to the digitonin-permeabilized cells, and Ca^2+^ release from the ER was monitored by changes in fluo-3 fluorescence. [Fig. 8](#fig8){ref-type="fig"} shows that InsP~3~-induced Ca^2+^ release from the ER was indistinguishable in the wild-type (K41) and calreticulin-deficient (K42) cells, indicating that there is no difference in function of the InsP~3~Rs in the different cell types.

![**Ca^2^** ^+^ **release in saponin-permeabilized calreticulin-deficient cells.** Wild-type (K41) and calreticulin-deficient (K42) cells were loaded with a fluorescent Ca^2+^ indicator fluo-3 and permeabilized with saponin. (A) InsP~3~ (10 μM) was added at the time indicated in the figure. (B) Basal \[Ca^2+^\]~c~ in InsP~3~ incubated wild-type (white bar) and calreticulin-deficient (black bar). Data are means ± SD (*n* = 3).](0102073f8){#fig8}

Since InsP~3~-induced Ca^2+^ release in permeabilized *crt* ^−^ *^/^*− cells is normal, the impaired bradykinin-induced Ca^2+^ release in intact cells could result from a deficiency in InsP~3~synthesis. To investigate this possibility, we incubated wild-type and calreticulin-deficient cells with 200 nM bradykinin and then measured InsP~3~ levels. [Fig. 9](#fig9){ref-type="fig"} A shows that the incubation with bradykinin resulted in significant synthesis of InsP~3~ in the K41 cells. In contrast, when calreticulin-deficient K42 cells were treated with bradykinin there was no detectable synthesis of InsP~3~ ([Fig. 9](#fig9){ref-type="fig"} A). We conclude that impairment of bradykinin-induced Ca^2+^ release in *crt* ^−^ *^/^*− K42 cells likely results from a failure to synthesize InsP~3~.

![**InsP~3~ production and \[^3^H\]bradykinin binding in calreticulin-deficient cells.** (A) InsP~3~ synthesis was measured in wild-type (K41) and calreticulin-deficient (K42) cells incubated in the absence (*−*) or presence (+) of bradykinin as described in Materials and methods. Data are means ± SD (*n* = 3). (B) \[^3^H\]bradykinin binding to wild-type (K41), calreticulin-deficient (K42), and calreticulin-deficient cells transfected with calreticulin expression vector (K42CRT).](0102073f9){#fig9}

Bradykinin binding in calreticulin-deficient cells
--------------------------------------------------

Our results indicate that bradykinin-dependent signaling is impaired in calreticulin-deficient cells and that this results from impaired InsP~3~ synthesis. Therefore, we measured bradykinin binding to *crt* ^−^ *^/^*− K42 cells. [Fig. 9](#fig9){ref-type="fig"} B shows that binding of \[^3^H\]bradykinin to wild-type K41 cells was saturable with a B~max~ of ∼2.5 ± 0.3 pmol/mg of total cell protein (*n* = 3). Scatchard analysis of the specific binding data gave an apparent dissociation constant (*K* ~d~) of 230 ± 20 pM. These values are in agreement with previously reported *K* ~d~ and B~max~ values for bradykinin receptors ([@bib23]). In contrast, the binding of bradykinin to calreticulin-deficient cells was significantly reduced (B~max~ \< 0.5 ± 0.01 pmol/mg of protein; *n* = 3) ([Fig. 9](#fig9){ref-type="fig"} B), which would explain why these cells show impairment of bradykinin-induced Ca^2+^ release ([Fig. 4](#fig4){ref-type="fig"}). K42CRT cells, which express calreticulin and exhibit normal bradykinin-induced Ca^2+^ release ([Fig. 4](#fig4){ref-type="fig"}), showed bradykinin binding comparable to that seen in wild-type cells (B~max~ 2.7 ± 0.3 pmol/mg of total cell protein; *n* = 3; *K* ~d~ of 225 ± 25 pM) ([Fig. 9](#fig9){ref-type="fig"} B). This was despite of a slightly lower level of expression of the bradykinin receptor in K42CRT cells ([Fig. 7](#fig7){ref-type="fig"} A). We concluded that bradykinin binding to its receptor is inhibited in calreticulin-deficient cells.

N **+** P domain of calreticulin restores bradykinin-induced Ca^2**+**^ release from K42 cells
----------------------------------------------------------------------------------------------

The data presented in [Figs. 4](#fig4){ref-type="fig"} and [9](#fig9){ref-type="fig"} indicate that the impairment of bradykinin-induced Ca^2+^ release in calreticulin-deficient cells results from the failure of bradykinin to bind to its receptor. This indicates that the bradykinin receptor may be misfolded and therefore unable to bind bradykinin. In preliminary experiments, we showed that calreticulin and bradykinin receptor form complexes, which can be immunoprecipitated (unpublished data), indicating that calreticulin may play a role in folding of the bradykinin receptor. This presented us with a unique opportunity to investigate the role of calreticulin\'s different domains in its function as a chaperone. We used bradykinin-induced changes in \[Ca^2+^\]~c~ as a measure of the function of the bradykinin receptor. Cells were loaded with fura-2, stimulated with 200 nM bradykinin, and changes in \[Ca^2+^\]~c~ were monitored. As shown in [Fig. 10](#fig10){ref-type="fig"} , in K42 *crt* ^−^ *^/^*− cells expressing calreticulin (K42CRT), bradykinin-induced Ca^2+^ release was restored to the levels seen in wild-type cells. This indicates that full-length calreticulin is required for normal ligand binding to the receptor. Bradykinin-induced Ca^2+^ release was also reestablished in K42 cells after transfection with the N + P domain of calreticulin ([Fig. 10](#fig10){ref-type="fig"} B, *K42N*+P). However, it was not reestablished in cells expressing the P + C domain of the protein ([Fig. 10](#fig10){ref-type="fig"} B, *K42P*+C). This indicates that the N and P domain of calreticulin may play a role in peptide binding and/or folding of the bradykinin receptor in mouse embryonic fibroblasts.

![**Role of the N** + **P domain of calreticulin in bradykinin-induced Ca^2^** ^+^ **release.** Cells were loaded with the fluorescent Ca^2+^ indicator fura-2 and stimulated with 200 nM bradykinin. A shows a basal \[Ca^2+^\]~c~, and B shows the amount of Ca^2+^ released by 200 nM bradykinin. K42, calreticulin-deficient cells; K42CRT, K42 cells transfected with calreticulin expression vector; K42N+P, K42 cells transfected with N + P domain expression vector; K42P+C, K42 cells transfected with P + C domain expression vector. Data are means ± SD (*n* = 3).](0102073f10){#fig10}

Discussion
==========

In this study, we took advantage of a new calreticulin-deficient cell line, which enabled us to address some of the many outstanding questions regarding the function of calreticulin and its distinct structural domains in the lumen of the ER. We found that calreticulin-deficient cells have impaired bradykinin-induced Ca^2+^ release, which results from a dysfunctional bradykinin receptor. The dysfunction probably arises because the receptor is incorrectly folded and as a result is unable to bind its ligand. Since the receptor cannot bind the ligand, it fails to initiate the signal transduction cascade, which normally leads to production of InsP~3~ and Ca^2+^ release from the ER via the InsP~3~R. These are the first studies in which the function of calreticulin and of its distinct domains have been tested against a calreticulin-deficient background. In these studies, we show that the C domain of calreticulin plays a critical role in determining the Ca^2+^ storage capacity of the ER and that the N + P domain but not the C domain may play a role in the protein\'s chaperone function. This study shows that distinct regions (domains) of calreticulin perform specialized functions in the ER lumen.

We have shown here that calreticulin plays an important role in determining the Ca^2+^ storage capacity of the ER. This fits with previous work, which has indicated that overexpression of calreticulin increases the Ca^2+^ capacity of InsP~3~-sensitive Ca^2+^ stores ([@bib2]; [@bib25]; [@bib12]; [@bib36]). Specifically, we found that there is a significant decrease in the Ca^2+^ storage capacity of the ER in calreticulin-deficient mouse embryonic fibroblasts. This finding is in disagreement with the results of other work in which calreticulin-deficient embryonic stem cells were used ([@bib6]). The cause of this discrepancy is not clear, but it may result from the relatively harsh conditions required for the selection of calreticulin-deficient embryonic stem cells. Importantly, we found that expression of either full-length calreticulin or its P + C domain in calreticulin-deficient fibroblasts restored the Ca^2+^ capacity of the ER to normal levels. This indicates that the P + C domains of calreticulin somehow help to determine the Ca^2+^ storage capacity in the lumen of the ER. This most likely occurs through the C domain of calreticulin, which binds Ca^2+^ with high capacity ([@bib27]), but at this stage a contribution by the P domain cannot be ruled out because we have been unable to express the C domain of calreticulin alone. Despite this, it is unlikely that the P domain has a role because expression of the N + P domain of calreticulin does not affect the Ca^2+^ storage capacity of the ER. For many years, it has been hypothesized that the C domain of calreticulin plays a role in determining the Ca^2+^ storage capacity of the ER. These studies provide the first direct evidence that this is indeed the case. Interestingly, although calreticulin-deficiency has a profound effect on the Ca^2+^ storage capacity of the ER it does not appear to affect the free \[Ca^2+^\]~ER~ as determined using cameleon techniques.

There are many obvious questions posed by the finding that calreticulin affects the Ca^2+^ storage capacity of the ER. For example, what are the physiological consequences of modulating the Ca^2+^ storage capacity of the ER? It has already been suggested that changes in Ca^2+^ concentration in the lumen of the ER may profoundly affect store-operated Ca^2+^ influx ([@bib12]). These kinds of changes may also be involved in regulation of Ca^2+^ transport ([@bib19]), protein--protein interactions, and chaperone function in the ER ([@bib7]). Further, recent reports indicate that the Ca^2+^ storage capacity of the ER may play a role in determining cell sensitivity to apoptosis. For example, cells that overexpress Bcl-2 have a lower Ca^2+^ in the lumen of the ER and are more resistant to apoptosis ([@bib14]; [@bib31], [@bib32]). In addition, calreticulin knockout cells, which have reduced intraluminal Ca^2+^ concentrations, are also resistant to apoptosis ([@bib29]).

The nuclear export of the glucocorticoid receptor is inhibited in calreticulin-deficient cells ([@bib18]). Calreticulin may play a role in this directly or alternatively, and these effects might be exerted through calreticulin\'s role in determining the Ca^2+^ storage capacity of the ER (and the nuclear envelope). It seems that many of the diverse functions proposed for calreticulin ([@bib27]) might be explained by its effects on the ER Ca^2+^ storage capacity as described here and by others ([@bib2]; [@bib25]; [@bib12]; [@bib36]).

Bradykinin-dependent Ca^2+^ signaling is impaired in calreticulin-deficient cells ([@bib26]). At least partly, this may explain why calreticulin deficiency is lethal. The Ca^2+^ responses to bradykinin are also diminished as a result of antisense oligodeoxynucleotide downregulation of calreticulin expression ([@bib21]). Normally bradykinin binds to a cell surface receptor, and this leads to the activation of PLC followed by the synthesis of InsP~3~ and the release of Ca^2+^ from ER stores via the InsP~3~R ([@bib16]). Since calreticulin is resident in the lumen of the ER, we thought that the impairment of bradykinin-induced Ca^2+^ release in calreticulin-deficient cells might result from a direct effect on InsP~3~R function. However, in this study we have shown that calreticulin-deficient cells exhibit normal InsP~3~-induced Ca^2+^ release but fail to produce InsP~3~ in response to bradykinin. Although the calreticulin-deficient cells have somewhat lower levels of the InsP~3~R, its function is apparently unaffected. This indicates that cells can tolerate some change in the expression of InsP~3~R without compromising the ER\'s ability to release Ca^2+^. It is not clear why expression of the InsP~3~R is decreased in calreticulin-deficient cells, but Ca^2+^ and calcineurin may play a role. Calcineurin affects expression of the InsP~3~R at the transcriptional level ([@bib15]) and calcineurin-dependent transcriptional processes are impaired in calreticulin-deficient cells.

Although the level of the bradykinin receptor is reduced in *crt* ^−^ *^/^*− cells, its targeting to the cell surface is unchanged, indicating that the absence of calreticulin does not affect its intracellular trafficking. Decreased expression of the bradykinin receptor may be due to increased degradation of the receptor in calreticulin-deficient cells. Our results indicate that calreticulin-deficient cells do not show bradykinin-induced Ca^2+^ release because the bradykinin receptor is unable to bind its ligand. If the bradykinin cannot bind, the receptor is unable to stimulate phospholipase C activity and synthesis of InsP~3~. Bradykinin-induced Ca^2+^ release can be rescued in *crt* ^−^ *^/^*− cells by reintroduction of full-length calreticulin. Importantly, the N + P domain of calreticulin is involved in this restoration, whereas the P + C domain is not. We conclude that the N domain of calreticulin is somehow essential for enabling interaction between the bradykinin receptor and its ligand, most likely through assisting in proper folding of the receptor\'s ligand-binding domain. Although we do not have direct evidence for this, it is conceivable that the N domain may directly interact with bradykinin receptor or it may recruit other chaperones necessary for the receptor folding and/or posttranslational modification. For example, the N domain interacts in vitro with ERp57 ([@bib8]), and this may be critical for proper folding of the ligand binding of the receptor. At present, the chaperone function of the P domain is not clear. This study indicates that either the P domain plays less important chaperone role, or most likely its chaperone function requires the presence of the N domain. However, this is the first evidence that the chaperone function of calreticulin may be also contained in the N domain of the protein.

It is widely thought that the central P domain of calreticulin can act as a chaperone for glycosylated proteins because of its amino acid sequence similarities to calnexin and its lectin-like activity. However, a series of in vitro experiments indicate that calreticulin may also function as a molecular chaperone for nonglycosylated proteins ([@bib34]). Both ATP and Zn^2+^ enhance calreticulin\'s ability to complex with unfolded nonglycosylated substrates in vitro ([@bib34]). This likely occurs because of the dramatic conformational change, which occurs in calreticulin in the presence of Zn^2+^ ([@bib20]). Calreticulin binds Zn^2+^ at its N domain ([@bib27]). The amino acid sequence of the N domain is extremely conserved among all calreticulins and is also unique to calreticulin ([@bib27]). This observation supports the suggestion that the N domain of calreticulin has a highly specific function, which may include the folding of specific substrates. The bradykinin receptor may be such a substrate. Calreticulin and calnexin both interact with monoglucosylated carbohydrates and therefore share many glycosylated substrates. However, each one also interacts with a significantly different spectrum of glycoproteins and proteins ([@bib10]). The N domain of calreticulin may assist in recognition of calreticulin-specific substrates such as the bradykinin receptor (this study). Notably, in support of this suggestion bradykinin-dependent Ca^2+^ release is not altered in calnexin-deficient cells (unpublished data).

In summary, we report here that calreticulin plays an important role in Ca^2+^ homeostasis in vivo. We show that the C domain of calreticulin is involved in determining the Ca^2+^ storage capacity of the ER and that the N + P domain may play a role as a chaperone. It is clear that the chaperone functions of calreticulin are tightly linked with its role in Ca^2+^ homeostasis, and in this work specifically it appears that improper binding of bradykinin to the receptor and/or improper folding of the bradykinin receptor affect its ability to induce Ca^2+^ release from ER Ca^2+^ stores. These studies indicate that distinct regions (domains) of calreticulin perform specialized functions in the ER lumen.

Materials and methods
=====================

Cell culture and DNA constructs
-------------------------------

Mouse embryonic fibroblasts were isolated from calreticulin-deficient and wild-type embryos, immortalized, and designated K41 and K42, respectively ([@bib29]). K42 *crt* ^−^ *^/^*− cells were transfected with the pcDNA3 expression vector containing cDNA encoding rabbit calreticulin to generate *crt* ^−^ *^/^*− cell lines expressing recombinant calreticulin (designated K42CRT). K42 cells were also transfected with expression vectors encoding the N + P domain or P + C domain of calreticulin to generated K42N+P and K42P+C lines, respectively. cDNA encoding the N + P domain of calreticulin (amino acid residues 1--287) was synthesized by PCR-driven reaction using the following oligodeoxynucleotides with 5′ flanking EcoR1 (primer N5′) and Kpn1 (primer P3′) restriction sites: N5′, 5′-ATATGAATTCATGCTGCTCCCTGTGCCGCT-3′ and P3′, 5′-ATATCTCGAGGTCGGGCGAGTACTCGGGGT-3′.

cDNA encoding the P + C domain of the protein (amino acid residues 172--401) was synthesized by PCR-driven reaction using the following P5′ and C3′ primers with 5′ flanking Kpn1 and Xho1, respectively: P5′, 5′-ATATGGTGACCAACAGCCAGGTGGAGTCGGG-3′ and C3′, 5′-ATATCTCGAGGCCGGCGGCCGCCTCCTCCT-3′.

cDNA for the N + P and P + C domain was preceded by cDNA encoding calreticulin signal sequence and COOH-terminal KDEL ER retrieval signal.

SDS-PAGE and Western blot analysis
----------------------------------

Cells were lysed, and proteins were separated by SDS-PAGE (10% acrylamide) and transferred to nitrocellulose membrane ([@bib25]). Blots were also probed with goat and rabbit anticalreticulin ([@bib29]), antibradykinin B2 receptor antibodies ([@bib5]), or rabbit anti-SERCA2 antibodies at a 1:1,000 dilution ([@bib22]).

To assess the level of InsP~3~R protein, microsomal membranes were isolated from wild-type (K41) and *crt* ^−^ *^/^*− (K42) cells ([@bib22]) and from RBL-2H3 cells as control ([@bib35]). Membrane proteins were separated on SDS-PAGE, transferred to Immobilon-P and probed with isoform-specific antibodies against InsP~3~R type 1 (Rbt03, dilution 1:1,000), InsP~3~R type 2 (Rbt02, dilution 1:200), or InsP~3~R type 3 (I31220, dilution 1:2,000; Transduction Laboratories) ([@bib30]; [@bib11]). Quantification of the immunoreactive bands was performed after incubation with secondary antibodies coupled to alkaline phosphatase detection using Vistra™ enhanced chemifluorescence and fluorimaging as described before ([@bib35]). Statistical analysis of the InsP~3~R isoforms levels in the K41 and K42 cells was performed using the paired Student\'s *t* test after normalization of the levels to those found in microsomes of RBL-2H3 cells.

Reverse transcriptase PCR analysis of InsP~3~R mRNA
---------------------------------------------------

Relative levels of mRNA encoding different isoforms of InsP~3~R were determined by reverse transcriptase PCR ([@bib11]). PCR products and restriction fragments were separated on a 6% acrylamide gel and visualized by staining with Vistra Green (followed by fluorimaging and quantitative analysis on a Storm840 FluoroImager equipped with the ImageQuaNT 4.2 software.) GAPDH mRNA was used as an internal standard.

Total and free ER luminal Ca^2**+**^ concentrations
---------------------------------------------------

The total Ca^2+^ in ER Ca^2+^ stores was estimated using ^45^Ca^2+^ (10 μCi/ml) as described earlier ([@bib25]). Free \[Ca^2+^\]~ER~ was estimated by dual emission ratio imaging using the ER-targeted yellow cameleon (YC4~ER~) ([@bib28]; [@bib1]). Cameleon fluorescence was imaged at 37°C on a ZEISS Axiovert S100 TV equipped with 430 ± 10 nm excitation and two emission filters alternated by a filterwheel. Images were acquired on a 12-bit cooled CCD camera controlled by the Metamorph/Metafluor versus 3.5 software. \[Ca^2+^\] was calibrated from the YC4~ER~ fluorescence ratio R (535/475 nm) using the following equation:

\[Ca^2^+\] = *K*′~d~\[(*R* − (*R* ~min~ + 14 / 100\*(*R* ~max~ − *R* ~min~))) / (*R* ~max~ − *R*)\]^(1/n)^

where *R* ~max~ = ratio obtained in the presence of 10 μM ionomycin and 20 mM CaCl~2~, *R* ~min~ = ratio obtained in the presence of 10 μM ionomycin and 20 mM EGTA, *K*′~d~ = 292 μM, the apparent dissociation constant, and *n* = 0.60, the Hill coefficient of the fitted Ca^2+^ calibration curve. This curve was obtained in situ on mouse embryonic fibroblasts expressing YC4~ER~, permeabilized with ionomycin (10 μM) and digitonin (5 μg/ml), and incubated with different Ca^2+^-containing solutions buffered with 5 mM EGTA and 5 mM HEEDTA below 100 μM free Ca^2+^ calculated according to [@bib4].

Cytoplasmic Ca^2**+**^ measurements
-----------------------------------

For measurement of \[Ca^2+^\]~c~, cells (1.5 × 10^6^/ml) were loaded with the fluorescent Ca^2+^ indicator fura-2/AM (2 μM) ([@bib25]). Cells were stimulated with 200 nM bradykinin, 100 μM carbachol, 1 μM angiotensin II, 50 nM bombesin, 10 mM caffeine, or 25 ng PDGF/ml of medium. For direct addition of InsP~3~, cells were permeabilized with saponin ([@bib13]).

InsP~3~ level measurement
-------------------------

For InsP~3~ level measurements K41 and K42 (4 × 10^7^ cells), cells were incubated for 15 s with 200 nM bradykinin, and the reaction was terminated by addition of an equal volume of 15% trichloroacetic acid. Acid-treated cells were centrifuged at 3,000 *g* for 15 min at 4°C, extracted with water-saturated diethyl ether, neutralized with NaHCO~3~ followed by the [d]{.smallcaps}-*myo*-\[^3^H\]InsP~3~--binding assay, which was carried out as recommended by the manufacturer (Amersham Pharmacia Biotech).

Bradykinin binding
------------------

Cells were plated at 2 × 10^4^ cells/ml in 24-well (1 ml/well) and equilibrated on ice for 10 min with a binding buffer containing 20 mM Hepes, pH 7.4, 17 mM NaCl, 5.4 mM KCl, 0.44 mM KH~2~PO~4~, 0.63 mM CaCl~2~, 0.21 mM MgSO~4~, 0.34 mM Na~2~HPO~4~, 110 mM *N*-methylglutamine, 0.1% BSA, and 2 mM bacitracin. Cells were then incubated with different concentrations of \[^3^H\]bradykinin (0.38--6.4 nM) in the presence or absence of 10 μM bradykinin. Cells were washed with a binding buffer, resuspended at 250 μl/well in ice-cold 100 mM NaOH and counted by scintillation counting. Binding assays were performed for 4 h at 4°C in triplicate.

Immunostaining, fluorescence microscopy, and flow cytometry
-----------------------------------------------------------

Immunostaining and confocal microscopy were carried out as previously described ([@bib29]). Goat antibodies against calreticulin (diluted 1:50), rabbit antibodies against Grp94 (diluted 1:50), PDI (diluted 1:50), and bradykinin receptor (diluted 1:100) were used. The secondary antibodies were: FITC-conjugated donkey anti--goat IgG (H + L) (diluted 1:50) and FITC-conjugated goat anti--rabbit IgG (H + L) (diluted 1:50).

For flow cytometry, fibroblasts were suspended in a solution containing 1 mM EDTA, 150 mM NaCl, 50 mM Tris, pH 7.3, washed, incubated with PBS containing 2% FBS, and labeled with rabbit antibradykinin receptor antibodies at a 1:10 dilution for 20 min at 4°C. Secondary antibody was anti--rabbit FITC antibody at a 1:50 dilution. Analysis was carried out with a Becton Dickinson FACScan using CellQuest software. Results are presented as the relative mean fluorescence intensity of the population labeled with primary and secondary antibodies minus that obtained with secondary antibody alone. Results shown are representative of five experiments.
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